Bionest

Artificial Intelligence and Real-time Data Improving Hospital Performance, Reducing Costs

Air traffic control-like, multiple screen “command centers,” are proving to be very effective tools for a small handful of busy hospitals to improve workflow efficiency, reduce wait times, allocate resources, and better orchestrate complex patient care and treatment.  The new systems combine artificial and human intelligence to analyze real-time data from machines, devices and electronic...

Bionest

“All of Us” Achieves Substantial Recruitment Milestone in Record Time

In 2015, the U.S. National Institutes of Health (NIH) announced plans for a major precision medicine initiative. The program is designed to take into account individual differences in lifestyle, environment and biology by gathering health data over time from more than a million people across the country. Its ultimate goal is to accelerate medical research and...

Bionest

A Crowded Field for Migraine Therapies, Where Recently There Were None

Back in March, when we first wrote about migraine drug development, there were no approved therapies addressing the underlying mechanisms of these painful, sometimes chronic, headaches — the most prevalent neurological disorder worldwide. Now, three such drugs have reached the market.   The three drugs — Aimovig (erenumab) from Amgen/Novartis, Ajovy (fremanezumab) from Teva Pharmaceuticals,...

Bionest

DEA Greenlights Epidiolex Launch with Drug Schedule Reclassification

Earlier this year, we wrote that GW Pharmaceuticals was poised to receive the first approval from the U.S. Food and Drug Administration (FDA) for a drug derived from the cannabis plant — Epidiolex (cannabidiol, also known as CBD), a treatment for seizures related to Lennox-Gastaut syndrome and Dravet syndrome, rare forms of epilepsy. The FDA...